Articles related to Oncology, Radiation

Explore innovative options for patients with pancreas, liver and biliary cancers at the Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The FDA’s recent approval of toripalimab, based on the JUPITER-02 and POLARIS-02 clinical trials, marks a significant milestone in the treatment of nasopharyngeal carcinoma. With a median progression-free survival of 11.7 months, toripalimab has shown promising results in improving patient outcomes.

The recent suspension of Dr. Benjamin Neel, former director of NYU’s Perlmutter Cancer Center, underscores the importance of academic integrity in the medical field. As healthcare professionals, it’s crucial to uphold the highest standards of conduct in our research.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

With 40% of us expected to develop cancer in our lifetime and 20% likely to die from it, the need for advanced care is more urgent than ever. This collaboration between Dana-Farber and BIDMC represents a significant step towards meeting this need.